Dr. Angie Beltsos on the advantages of PGS for IVF practices | Illumina Video

10 July 2015

Join Angie Beltsos, MD, as she explores the latest advancements in fertility. Topics include minimizing risk of hyperstimulation, optimizing health of the transferred embryo, and improving the odds of singleton birth with frozen single euploid embryo transfer. Providing Preimplantation Genetic Screening (PGS) [http://www.illumina.com/clinical/reproductive-genetic-health.html] requires managing patient expectations, helping the medical team understand the technology, and guiding the couple to success.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.